Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Share-based Compensation (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Share-based Compensation for 4 consecutive years, with $22.7 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 3.38% to $22.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $93.8 million through Dec 2025, up 10.01% year-over-year, with the annual reading at $93.8 million for FY2025, 10.01% up from the prior year.
  • Share-based Compensation hit $22.7 million in Q4 2025 for Axsome Therapeutics, down from $23.1 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $37.7 million in Q4 2022 to a low of $9197.0 in Q3 2022.
  • Historically, Share-based Compensation has averaged $18.0 million across 4 years, with a median of $20.8 million in 2024.
  • Biggest YoY gain for Share-based Compensation was 177871.08% in 2023; the steepest drop was 49.83% in 2023.
  • Year by year, Share-based Compensation stood at $37.7 million in 2022, then plummeted by 49.83% to $18.9 million in 2023, then rose by 16.24% to $22.0 million in 2024, then increased by 3.38% to $22.7 million in 2025.
  • Business Quant data shows Share-based Compensation for AXSM at $22.7 million in Q4 2025, $23.1 million in Q3 2025, and $24.6 million in Q2 2025.